MX2021004058A - Construcciones de anticuerpos que se unen a 4-1bb y a antigenos asociados a tumores y sus usos. - Google Patents
Construcciones de anticuerpos que se unen a 4-1bb y a antigenos asociados a tumores y sus usos.Info
- Publication number
- MX2021004058A MX2021004058A MX2021004058A MX2021004058A MX2021004058A MX 2021004058 A MX2021004058 A MX 2021004058A MX 2021004058 A MX2021004058 A MX 2021004058A MX 2021004058 A MX2021004058 A MX 2021004058A MX 2021004058 A MX2021004058 A MX 2021004058A
- Authority
- MX
- Mexico
- Prior art keywords
- constructions
- antibodies
- bind
- binding domain
- associated antigens
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862744059P | 2018-10-10 | 2018-10-10 | |
| PCT/CA2019/051448 WO2020073131A1 (en) | 2018-10-10 | 2019-10-10 | Antibody constructs binding 4-1bb and tumor-associated antigens and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021004058A true MX2021004058A (es) | 2021-06-04 |
Family
ID=70164178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021004058A MX2021004058A (es) | 2018-10-10 | 2019-10-10 | Construcciones de anticuerpos que se unen a 4-1bb y a antigenos asociados a tumores y sus usos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230052369A1 (https=) |
| EP (1) | EP3864051A4 (https=) |
| JP (1) | JP7596263B2 (https=) |
| KR (1) | KR20210076918A (https=) |
| CN (2) | CN112996809A (https=) |
| AU (1) | AU2019356806B2 (https=) |
| BR (1) | BR112021006784A2 (https=) |
| CA (1) | CA3113539A1 (https=) |
| MX (1) | MX2021004058A (https=) |
| WO (1) | WO2020073131A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021207827A1 (en) * | 2020-04-15 | 2021-10-21 | Zymeworks Inc. | Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof |
| MX2022013944A (es) * | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| CN112794911B (zh) * | 2021-04-14 | 2021-08-03 | 上海偌妥生物科技有限公司 | 人源化抗叶酸受体1抗体及其应用 |
| CA3216342A1 (en) * | 2021-04-23 | 2022-10-27 | Hassan ISSAFRAS | Anti-gpc3 antibodies, multispecific antibodies and methods of use |
| CN116769041A (zh) * | 2022-03-10 | 2023-09-19 | 合肥瀚科迈博生物技术有限公司 | 靶向msln和4-1bb的双特异性抗体及其应用 |
| EP4584300A1 (en) * | 2022-09-06 | 2025-07-16 | TJ Biopharma (Shanghai) Co., Ltd. | Multispecific constructs and uses thereof |
| US20240190958A1 (en) * | 2022-10-18 | 2024-06-13 | Tubulis Gmbh | Novel antibody drug conjugates with novel napi2b antibodies, therapeutic methods and uses thereof |
| WO2025131027A1 (en) * | 2023-12-21 | 2025-06-26 | Lanova Medicines Development Co., Ltd. | Anti-slc34a2/anti-4-1bb antibodies and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9402865B2 (en) * | 2011-01-18 | 2016-08-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| EP3593812A3 (en) * | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| AU2017252233A1 (en) * | 2016-04-22 | 2018-11-15 | Alligator Bioscience Ab | Novel bispecific polypeptides against CD137 |
| KR20240000650A (ko) * | 2016-10-19 | 2024-01-02 | 인벤라 인코포레이티드 | 항체 구조물 |
| IL268836B2 (en) * | 2017-02-24 | 2024-04-01 | Macrogenics Inc | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof |
-
2019
- 2019-10-10 CN CN201980066726.6A patent/CN112996809A/zh active Pending
- 2019-10-10 EP EP19871359.6A patent/EP3864051A4/en active Pending
- 2019-10-10 AU AU2019356806A patent/AU2019356806B2/en active Active
- 2019-10-10 CN CN202511697951.3A patent/CN121758617A/zh active Pending
- 2019-10-10 KR KR1020217011608A patent/KR20210076918A/ko active Pending
- 2019-10-10 JP JP2021520222A patent/JP7596263B2/ja active Active
- 2019-10-10 MX MX2021004058A patent/MX2021004058A/es unknown
- 2019-10-10 WO PCT/CA2019/051448 patent/WO2020073131A1/en not_active Ceased
- 2019-10-10 BR BR112021006784-1A patent/BR112021006784A2/pt unknown
- 2019-10-10 CA CA3113539A patent/CA3113539A1/en active Pending
-
2021
- 2021-04-09 US US17/226,834 patent/US20230052369A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3113539A1 (en) | 2020-04-16 |
| KR20210076918A (ko) | 2021-06-24 |
| JP7596263B2 (ja) | 2024-12-09 |
| JP2022504826A (ja) | 2022-01-13 |
| AU2019356806A1 (en) | 2021-05-27 |
| EP3864051A4 (en) | 2022-11-23 |
| BR112021006784A2 (pt) | 2021-09-21 |
| EP3864051A1 (en) | 2021-08-18 |
| WO2020073131A1 (en) | 2020-04-16 |
| AU2019356806B2 (en) | 2026-03-05 |
| CN121758617A (zh) | 2026-03-31 |
| US20230052369A1 (en) | 2023-02-16 |
| CN112996809A (zh) | 2021-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021004058A (es) | Construcciones de anticuerpos que se unen a 4-1bb y a antigenos asociados a tumores y sus usos. | |
| CL2023001064A1 (es) | Proteína de unión al antígeno anti-steap1 | |
| IL280467A (en) | Antibody constructs for cldn18.2 and cd3 | |
| CL2020002305A1 (es) | Uso de anticuerpos sirpa v1 antihumanos y procedimiento de producción de anticuerpos anti-sirpa v1 | |
| EA202190542A1 (ru) | Сконструированные биспецифические белки | |
| IL291545A (en) | Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof | |
| CL2019002855A1 (es) | Anticuerpos anti-ilt4 y fragmentos de unión a antígeno. | |
| AU2018258045A1 (en) | Chimeric antibody/T-cell receptor constructs and uses thereof | |
| EA202092847A1 (ru) | Антитела к cd3 и их применение | |
| BR112018014760A2 (pt) | anticorpos anti-ror1, anticorpos biespecíficos para ror1 x cd3 e métodos de uso dos mesmos | |
| EA201692504A1 (ru) | Триспецифичные связывающие молекулы и способы их применения | |
| CL2018002490A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866) | |
| CN110291109A (zh) | 人程序性死亡受体pd-1的单克隆抗体及其片段 | |
| EA201891582A1 (ru) | Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки | |
| AR101846A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| FI3608337T3 (fi) | Bispesifisiä t-solua aktivoivia antigeenia sitovia molekyylejä | |
| MX2023011121A (es) | Anticuerpos anti antigeno leucocito 37 (cd37) biespecificos, anticuerpos anti antigeno leucocito 37 (cd37) monoclonales y metodos de uso de los mismos. | |
| MX2021003636A (es) | Receptor antigenico quimerico. | |
| ES2572231T3 (es) | Anticuerpos monoclonales anti-IL-21 humana | |
| BR112016022841A8 (pt) | Anticorpo igm, iga, igg / igm ou igg / iga, ou um fragmento de ligação ao antígeno do mesmo, composição que o compreende e uso do mesmo | |
| BR112018070948A2 (pt) | anticorpos anti-psma e utilização dos mesmos | |
| EA201990672A1 (ru) | Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты | |
| IL289488A (en) | Monoclonal antibodies that bind egfrviii and their use | |
| EP4032907A4 (en) | Bcma-targeted antibody and chimeric antigen receptor |